APA (7th ed.) Citation

Aladul, M., Fitzpatrick, R., & Chapman, S. (2017). Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. BioDrugs, 31(6), 533. https://doi.org/10.1007/s40259-017-0252-3

Chicago Style (17th ed.) Citation

Aladul, Mohammed, Raymond Fitzpatrick, and Stephen Chapman. "Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK." BioDrugs 31, no. 6 (2017): 533. https://doi.org/10.1007/s40259-017-0252-3.

MLA (9th ed.) Citation

Aladul, Mohammed, et al. "Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK." BioDrugs, vol. 31, no. 6, 2017, p. 533, https://doi.org/10.1007/s40259-017-0252-3.